Dr. Reidy Lagunes on the Potential of Immunotherapy in NETs

Video

In Partnership With:

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

High mutational burdens exist in high-grade neuroendocrine carcinoma, non—small cell lung cancer (NSCLC), and melanoma, Reidy Lagunes explains. Therefore, since there are high response rates with immunotherapy in patients with NSCLC and melanoma, researchers hypothesize that such agents could demonstrate activity in the former tumor type, as well.

Interferon is one of the earliest and most common immunotherapy agents available, Lagunes says. However, though the agent shows promise, interferon is associated with flu-like symptoms, suggesting that other immunotherapies should be studied in this space.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD